PAHC vs DE

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -2. 2% for Deere & Company (DE). Deere & Company (DE) offers the better valuation at 32. 0x trailing P/E (33. 2x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Deere & Company (DE) is the cheapest at 32.

0x versus Phibro Animal Health Corporation at 49. 3x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 19. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Deere & Company wins at 2. 03x versus Phibro Animal Health Corporation's 2. 59x.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +136.

4%, compared to +58. 7% for Deere & Company (DE). Over 10 years, the gap is even starker: DE returned +676. 6% versus PAHC's +207. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Deere & Company (DE) is the lower-risk stock at 0.

56β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 145% more volatile than DE relative to the S&P 500. On balance sheet safety, Deere & Company (DE) carries a lower debt/equity ratio of 2% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -2. 2% for Deere & Company (DE). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 0. 0% for Deere & Company. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Deere & Company (DE) is the more profitable company, earning 11.

3% net margin versus 3. 7% for Phibro Animal Health Corporation — meaning it keeps 11. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DE leads at 18. 8% versus 8. 5% for PAHC. At the gross margin level — before operating expenses — DE leads at 36. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Deere & Company (DE) is the more undervalued stock at a PEG of 2. 03x versus Phibro Animal Health Corporation's 2. 59x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 19. 3x forward P/E versus 33. 2x for Deere & Company — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DE: 15. 0% to $680. 54.

All stocks in this comparison pay dividends.

Deere & Company (DE) offers the highest yield at 1. 1%, versus 0. 8% for Phibro Animal Health Corporation (PAHC).

For long-horizon retirement investors, Deere & Company (DE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

56), 1. 1% yield, +676. 6% 10Y return). Both have compounded well over 10 years (DE: +676. 6%, PAHC: +207. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PAHC (Healthcare) and DE (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PAHC is a small-cap high-growth stock; DE is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.